BIOQUAL, Inc., formerly Diagnon Corporation, develops, produces and sells diagnostic test kits incorporating monoclonal antibodies to diagnose certain anemias, infections, and parasitic diseases.
| Revenue (Most Recent Fiscal Year) | $48.87M |
| Net Income (Most Recent Fiscal Year) | $-1.05M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.73 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.95 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -1.32% |
| Return on Equity (Trailing 12 Months) | -1.74% |
| Return on Assets (Trailing 12 Months) | -1.09% |
| Current Ratio (Most Recent Fiscal Quarter) | -- |
| Quick Ratio (Most Recent Fiscal Quarter) | -- |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.70 |
| Exchange | -- |
| Sector | -- |
| Industry | -- |
| Common Shares Outstanding | 0.89M |
| Free Float | 0.54M |
| Market Capitalization | $34.44M |
| Average Volume (Last 20 Days) | 14.15 |
| Beta (Past 60 Months) | -0.17 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 39.24% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.50 |
| Dividend Yield (Based on Last Quarter) | 1.30% |